Contact Us

Retatrutide is an investigational multi-receptor agonist designed to support weight management and metabolic health. It is currently under clinical evaluation and not approved for general consumer use outside of research or prescribed medical oversight.

The main difference is the dosage strength. Retatrutide 20mg is typically used in early treatment or research stages, while Retatrutide 40mg is a higher concentration designed for advanced studies or specific protocols under medical guidance.

Retatrutide acts on multiple hormone pathways, including GLP-1, GIP, and glucagon receptors. This combined activity is believed to help regulate appetite, improve glucose metabolism, and support weight loss.

As of now, Retatrutide is still in clinical trials and not FDA-approved for commercial use. Access is limited to controlled research environments or through regulated healthcare channels.

Retatrutide should only be used by licensed researchers, healthcare professionals, or participants enrolled in clinical trials. It is not intended for self-administration or over-the-counter purchase.

Preliminary studies suggest Retatrutide may support weight reduction, improved insulin sensitivity, and enhanced metabolic health. However, more research is needed to confirm safety and efficacy.